O-prenylated 3-carboxycoumarins as a novel class of 15-LOX-1 inhibitors

PLoS One. 2017 Feb 9;12(2):e0171789. doi: 10.1371/journal.pone.0171789. eCollection 2017.

Abstract

Allyloxy, Isopentenyloxy, geranyloxy and farnesyloxy derivatives of 3-carboxycoumarin, at position 5, 6, 7, and 8, were synthesized and their inhibitory potency against human 15-lipoxygenase-1 (human 15-LOX-1) were determined. Among the synthetic coumarins, O-allyl and O-isopentenyl derivatives demonstrated no considerable lipoxygenase inhibition while O-geranyl and O-farnesyl derivatives demonstrated potent inhibitory activity. 5-farnesyloxy-3-carboxycoumarin demonstrated the most potent inhibitory activity by IC50 = 0.74 μM while 6-farnesyloxy-3-carboxycoumarin was the weakest inhibitor among farnesyl analogs (IC50 = 10.4 μM). Bonding affinity of the designed molecular structures toward 15-LOX-1 3D structure complexed with RS75091, as potent 15-LOX-1 inhibitor, was studied by utilizing docking analysis. There was a direct relationship between lipoxygenase inhibitory potency and prenyl length chain. The ability of the prenyl portion to fill the lipophilic pocket which is formed by Ile663, Ala404, Arg403, Ile400, Ile173 and Phe167 side chains can explain the observed relationship. Similarity rate between the docked models and complexed form of RS75091, from point of view of configuration and conformation, could explain inhibitory potency variation between each prenyloxy substitution of 3-carboxycoumarins.

MeSH terms

  • Arachidonate 15-Lipoxygenase / chemistry
  • Arachidonate 15-Lipoxygenase / metabolism*
  • Binding Sites
  • Coumarins / chemistry
  • Coumarins / classification
  • Coumarins / metabolism
  • Coumarins / pharmacology*
  • Humans
  • Lipoxygenase Inhibitors / chemistry
  • Lipoxygenase Inhibitors / classification
  • Lipoxygenase Inhibitors / pharmacology*
  • Models, Molecular
  • Molecular Docking Simulation
  • Molecular Structure
  • Prenylation
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Coumarins
  • Lipoxygenase Inhibitors
  • Arachidonate 15-Lipoxygenase

Grants and funding

The authors received no specific funding for this work.